Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.23 (
MMP
)
4,246
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A series of hydroxamic acids has been prepared as potential inhibitors of glutamate carboxypeptidase II (
GCP
II). Compounds based on a P1' residue (primed-side inhibitors) were more potent than those based on a P1 group (unprimed-side inhibitors). Inhibitory potency of the primed-side
GCP
II inhibitors was found to be dependent on the number of methylene units between the hydroxamate group and pentanedioic acid. Succinyl hydroxamic acid derivative, 2-(hydroxycarbamoylmethyl)pentanedioic acid, is the most potent
GCP
II inhibitor with an IC(50) value of 220nM. The comparison of the results to those of other classes of
GCP
II inhibitors as well as hydroxamate-based
MMP
inhibitors provides further insight into the structure-activity relationships of
GCP
II inhibition.
...
PMID:Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. 1279 12